The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. This week, the medicine, first approved in 2009, was listed as discontinued on the ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. “There's an evolution of our economic model that starts with [the] IRA (Inflation ...

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

Takeda has opened an innovation capability centre (ICC) in Bengaluru to leverage the local tech talent pool for building core digital skills. This new centre, part of their Data, Digital ...

Bone-chilling temperatures couldn’t keep the crowds away from Takeda’s Kendall Square campus on Tuesday to celebrate a milestone for the Japanese drugmaker’s new R&D tower. More than 250 ...

TOKYO ― Japanese trading house Marubeni said on Wednesday it is aiming for a net profit of more than 620 billion yen ($4 billion) in fiscal year 2027/2028, with shareholder returns of 40 percent which ...

See Correction/Clarification at the end of this article. After layoffs in 2024, Takeda is gearing up for a big 2025 that includes preparations to launch three new medicines, hiring, and finishing ...

TOKYO -- Japanese trading house Marubeni has agreed to invest in Phillips Pharma Group, which supplies medical goods in sub-Saharan Africa. The investment marks Marubeni's entry into the African ...

Ascentage, backed by Japan's biggest drugmaker Takeda Pharmaceutical (4502.T), opens new tab, is looking to raise $149 million by offering about 7.3 million American depositary shares at $20.34 each.

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S. business unit. As part of the executive transition, Weber will retire in June ...

Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), (OTCPK:AAPGV) which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering. In an SEC filing ...

Later during the conference, Takeda CEO Christophe Weber laid out the company's top pipeline prospects, a group of 6 drugs that could collectively generate $20 billion at peak. And Samsung ...